共 50 条
- [11] Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed-Ratio Combination vs. Insulin Glargine in Japanese Patients with T2DMDIABETES, 2019, 68Kaneto, HideakiTakami, AkaneSpranger, RobertAmano, AtsushiWatanabe, DaisukeNiemoeller, Elisabeth
- [12] Impact of Dose Capping in Insulin Glargine/Lixisenatide Fixed-Ratio Combination Trials in Patients with T2DDIABETES, 2017, 66 : A292 - A292Schmider, WolfgangBelder, ReneLee, MichelleMeng, ZhaolingNiemoeller, ElisabethSouhami, ElisabethWu, YujunMandema, JaapNewton, JohnMeneghini, LuigiFrias, Juan
- [13] Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed-Ratio Combination vs. Insulin Glargine in Patients with T2DM: The Lixi-Lan-L TrialDIABETES, 2016, 65 : A62 - A63Aroda, VanitaRosenstock, JulioWysham, CarolUnger, JeffreyBellido, DiegoGalvez, Guillermo GonzalezTakami, AkaneGuo, HailingNiemoeller, ElisabethSouhami, ElisabethBergenstal, Richard M.
- [14] iGlarLixi Fixed-Ratio Combination vs. Insulin Glargine and Lixisenatide in Patients with T2DM Treated Previously with Two Oral Antidiabetics: LixiLan-O Subgroup AnalysisDIABETES, 2017, 66 : LB35 - LB35Russell-Jones, DavidMccrimmon, Rory J.Barber, Thomas M.Baradez, CecileBaxter, Michael A.Davies, Melanie
- [15] Consistent Outcomes across Dose Ranges with Titratable LixiLan, Insulin Glargine/Lixisenatide Fixed-Ratio Combination, in the LixiLan-O TrialDIABETES, 2016, 65 : A264 - A264Henry, Robert R.Ahren, BoDavies, MelanieWu, YujunHandelsman, YehudaSouhami, ElisabethNiemoeller, ElisabethRosenstock, Julio
- [16] iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 DiabetesANNALS OF PHARMACOTHERAPY, 2017, 51 (11) : 990 - 999Goldman, JenniferTrujillo, Jennifer M.
- [17] Titratable Fixed-Ratio vs. Sequential Combination of Insulin Glargine and Lixisenatide: Propensity Score-Matched Analysis to Compare LixiLan-L and GetGoal Duo-2 TrialsDIABETES, 2017, 66 : A622 - A623Meier, Juris J.Vidal, JosepLiu, MinzhiPerfetti, RiccardoRosenstock, Julio
- [18] Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponentsDIABETES OBESITY & METABOLISM, 2017, 19 (12): : 1798 - 1804Davies, Melanie J.Leiter, Lawrence A.Guerci, BrunoGrunberger, GeorgeJavier Ampudia-Blasco, F.Yu, ChristineStager, WilliamNiemoeller, ElisabethSouhami, ElisabethRosenstock, Julio
- [19] Insulin Glargine/Lixisenatide Fixed-Ratio Combination Outcomes Are Similar for North American and Rest of World T2D PopulationsDIABETES, 2016, 65 : A277 - A277Dailey, GeorgeBailey, Timothy S.Bajaj, Harpreet S.Dex, TerryGroleau, MelanieStager, WilliamVinik, Aaron
- [20] Impact of Baseline HbA1c, BMI, and Diabetes Duration on the Efficacy and Safety of LixiLan (Insulin Glargine/Lixisenatide Titratable Fixed-Ratio Combination) vs. Insulin Glargine and Lixisenatide in the LixiLan-O TrialDIABETES, 2016, 65 : A268 - A268Davies, MelanieLeiter, Lawrence A.Grunberger, GeorgeAmpudia-Blasco, F. JavierGuerci, BrunoYu, ChristineStager, WilliamNiemoeller, ElisabethSouhami, ElisabethRosenstock, Julio